Trials / Completed
CompletedNCT00097487
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase IV, prospective, nonrandomized, community-based study of clinical outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.
Conditions
Timeline
- Start date
- 2000-11-30
- Completion
- 2004-09-30
- First posted
- 2004-11-25
- Last updated
- 2018-03-02
Source: ClinicalTrials.gov record NCT00097487. Inclusion in this directory is not an endorsement.